Envafolimab + pemetrexed

Envafolimab + pemetrexed is a combination therapy pairing two distinct medications with different mechanisms of action. Envafolimab is a novel fusion of a humanized single-domain PD-L1 antibody and human IgG1 crystalline fragment formulated for subcutaneous injection. It acts as an immune checkpoint inhibitor by blocking PD-L1, aiming to restore the immune system's ability to recognize and attack cancer cells. Envafolimab has been approved in China for microsatellite instability-high (MSI-H) cancer. Pemetrexed is an established antineoplastic agent, a folate analog, that inhibits multiple folate-dependent enzymes involved in DNA synthesis. It is approved for treating non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma, often in combination with other agents like cisplatin or pembrolizumab. The combination of immunotherapy (envafolimab) with chemotherapy (pemetrexed) represents a strategy to target cancer through complementary mechanisms: direct cytotoxicity via chemotherapy and immune system activation via immunotherapy. While both drugs have been studied in combination with other agents (envafolimab with carboplatin and etoposide; pemetrexed with various drugs), specific clinical trials or approvals for the exact combination of envafolimab and pemetrexed are not provided in the search results.